Article
Oncology
Shengxiang Ren, Jifeng Feng, Shenglin Ma, HuaJun Chen, Zhiyong Ma, Cheng Huang, Li Zhang, Jianxing He, Changli Wang, Jianying Zhou, Pongwut Danchaivijtr, Chin-Chou Wang, Ihor Vynnychenko, Kai Wang, Francisco Orlandi, Virote Sriuranpong, Ben Li, Jun Ge, Thao Dang, Caicun Zhou
Summary: KEYNOTE-033 is a multicountry, open-label, phase 3 study that compared the efficacy of pembrolizumab and docetaxel in mainland China, in previously treated, PD-L1-positive, advanced NSCLC patients. The study showed that pembrolizumab improved overall survival compared to docetaxel in patients with PD-L1 TPS >= 1%. However, statistical significance was not reached in patients with PD-L1 TPS >= 50%. The performance of pembrolizumab in treating NSCLC is consistent with previous observations.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein, Andrew S. Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario Velasco, Jose Lutzky, Emily Higgs, Riyue Bao, Timothy C. Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K. Sondak, Thomas F. Gajewski, Nikhil Khushalani, Jason J. Luke
Summary: This study is the first prospective study in melanoma of pembrolizumab plus low-dose ipilimumab after anti-PD-1/L1 immunotherapy failure, demonstrating significant antitumor activity and tolerability.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Song Chen, Zhiqiang Wu, Feng Shi, Qicong Mai, Liguang Wang, Fan Wang, Wenquan Zhuang, Xiaoming Chen, Huanwei Chen, Bo Xu, Jiaming Lai, Wenbo Guo
Summary: This retrospective study compared the clinical outcomes of pembrolizumab-lenvatinib-TACE and lenvatinib-TACE sequential therapy in Chinese uHCC patients with initial PD-L1 expression, indicating that the former had a higher conversion rate, longer OS and PFS.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Matthew H. Taylor, Emmett Schmidt, Corina Dutcus, Elaine M. Pinheiro, Yasuhiro Funahashi, Gregory Lubiniecki, Drew Rasco
Summary: The combination therapy of lenvatinib plus pembrolizumab demonstrates robust antitumor activity and durable responses across diverse tumor types with a manageable safety profile, making it a potentially important new regimen for several solid cancers that currently have limited therapeutic options.
Article
Oncology
Kazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, Kazumasa Komura, Takuo Hayashi, Wataru Fukuokaya, Ayako Ura, Taizo Uchimoto, Ko Nakamura, Tatsuo Fukushima, Yusuke Yano, Nobushige Takahashi, Keita Nakamori, Shoko Kinoshita, Tomohisa Matsunaga, Takeshi Tsutsumi, Takuya Tsujino, Kohei Taniguchi, Tomohito Tanaka, Hirofumi Uehara, Kiyoshi Takahara, Teruo Inamoto, Yoshinobu Hirose, Takahiro Kimura, Shin Egawa, Haruhito Azuma
Summary: The efficacy of pembrolizumab for patients previously treated with chemoradiation therapy (CRT) was found to be similar to those treated with total cystectomy (TC). Enhanced tumor regression might be expected with concurrent administration of chemotherapy and programmed cell death protein 1/PD-L1 inhibitor.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Joseph Mabbitt, Ian D. Holyer, James A. Roper, Ulf J. Nilsson, Fredrik R. Zetterberg, Lynda Vuong, Alison C. Mackinnon, Anders Pedersen, Robert J. Slack
Summary: This study found that Gal-3 can enhance the PD-1/PD-L1 immune axis and potentially contribute to immunosuppressive signaling mechanisms within the tumor microenvironment. Additionally, Gal-3 prevents atezolizumab and pembrolizumab from engaging with their respective immune checkpoint receptors. Reversal of this effect with the clinical candidate GB1211 offers a potential enhancing combination therapeutic with anti-PD-1 and -PD-L1 blocking antibodies.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Eun-Ji Lee, Ji Hye Kim, Tae In Kim, Yeon-Ji Kim, Malk Eun Pak, Chang Hyun Jeon, Yeo Jin Park, Wei Li, Young Soo Kim, Jang-Gi Choi, Hwan-Suck Chung
Summary: This study demonstrates the anticancer effects of Sanguisorbae Radix extract (SRE) through PD-1/PD-L1 blockade and the enhanced immuno-oncologic effects of combination therapy with SRE and pembrolizumab.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Immunology
Chengpei Zhu, Jingnan Xue, Yunchao Wang, Shanshan Wang, Nan Zhang, Yanyu Wang, Longhao Zhang, Xu Yang, Junyu Long, Xiaobo Yang, Xinting Sang, Haitao Zhao
Summary: The combination of Lenvatinib, PD-1/PD-L1 inhibitors, and Gemox chemotherapy is an effective and well-tolerated treatment option for patients with advanced biliary tract cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Kazushige Wakuda, Michitoshi Yabe, Hiroaki Kodama, Naoya Nishioka, Taichi Miyawaki, Eriko Miyawaki, Nobuaki Mamesaya, Takahisa Kawamura, Haruki Kobayashi, Shota Omori, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Hideyuki Harada, Masahiro Endo, Yasuhiro Gon, Toshiaki Takahashi
Summary: The study retrospectively reviewed patients with high PD-L1 TPS NSCLC who received Pembrolizumab as first-line treatment, finding that untreated brain metastasis did not significantly impact the efficacy of Pembrolizumab. There were no significant differences in PFS and OS between the BM group and non-BM group, as well as between the BM-T group and BM-not T group.
Article
Oncology
Matthew D. Hellmann, Pasi A. Janne, Mateusz Opyrchal, Navid Hafez, Luis E. Raez, Dmitry Gabrilovich, Fang Wang, Jane B. Trepel, Min-Jung Lee, Akira Yuno, Sunmin Lee, Susan Brouwer, Serap Sankoh, Lei Wang, David Tamang, Emmett Schmidt, Michael L. Meyers, Suresh S. Ramalingam, Elaine Shum, Peter Ordentlich
Summary: In patients with NSCLC who had previous experience with PD-(L)1, the combination of entinostat and pembrolizumab did not meet the primary response rate endpoint but provided a clinically meaningful benefit, with 9% of patients showing objective response. No new toxicities, including immune-related adverse events, were observed.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Vicky Makker, Nicoletta Colombo, Antonio Casado Herraez, Bradley J. Monk, Helen Mackay, Alessandro D. Santin, David S. Miller, Richard G. Moore, Sally Baron-Hay, Isabelle Ray-Coquard, Kimio Ushijima, Kan Yonemori, Yong Man Kim, Eva M. Guerra Alia, Ulus A. Sanli, Steven Bird, Robert Orlowski, Jodi McKenzie, Chinyere Okpara, Gianmaria Barresi, Domenica Lorusso
Summary: This article reports the final prespecified analysis of the Study 309/KEYNOTE-775, which is an open-label, randomized, phase III trial. The results show that lenvatinib plus pembrolizumab improves overall survival, progression-free survival, and objective response rate compared to chemotherapy in patients with advanced endometrial cancer. The combination therapy also demonstrates improved efficacy and manageable safety in various subgroups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng
Summary: This study aims to compare the cost-effectiveness of Pembro+Chemo and Pembro monotherapy as first-line treatments for metastatic non-squamous and squamous NSCLC patients. The results showed that Pembro+Chemo was not cost-effective for non-squamous NSCLC patients with PD-L1 expression >= 50%, while it was a cost-effective treatment for squamous NSCLC patients.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Haijing Deng, Anna Kan, Ning Lyu, Meng He, Xin Huang, Shuang Qiao, Shaolong Li, Wenhua Lu, Qiankun Xie, Huiming Chen, Jinfa Lai, Qifeng Chen, Xiongying Jiang, Shousheng Liu, Zhenfeng Zhang, Ming Zhao
Summary: Neutrophils play a controversial role in tumor development, with PD-L1(+) neutrophils inhibiting the cytotoxicity of anti-tumor immunity. Lenvatinib was found to induce CXCL2 and CXCL5 secretion, promoting recruitment of neutrophils in the tumor microenvironment. Inhibiting PD-L1(+) neutrophils with a COX-2 inhibitor could enhance the antitumor effect of lenvatinib by restoring T cell cytotoxicity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Charles S. Fuchs, Mustafa Ozguroglu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandala, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesinski, Christian Caglevic, Hyun C. Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter Thuss-Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie-Schin Shih, Kohei Shitara
Summary: In this long-term analysis, second-line pembrolizumab did not significantly improve overall survival but was associated with higher 24-month OS rates than paclitaxel in the CPS>=1 population. Pembrolizumab also increased overall survival benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer treatment-related adverse events (TRAEs) compared to paclitaxel.
Article
Oncology
Song Chen, Bo Xu, Zhiqiang Wu, Pengfei Wang, Weiguang Yu, Zhiyong Liu, Xiaoyong Huang, Yanqing Wu, Tengfei Li, Wenbo Guo
Summary: Among treatment-naive patients with unresectable hepatocellular carcinoma exhibiting PD-L1 staining, the PLH regimen may significantly improve survival benefits compared to the PL regimen with a controllable safety profile.
